Skip to main content
OpenTrials
Completed

NCT Number: NCT04079933

A Study to Evaluate Changes in Smokers Using An Oral Tobacco-Derived Nicotine Product

The purpose of this study was to estimate changes in biomarkers of exposure (BOE) in adult cigarette smokers using an oral tobacco-derived nicotine (OTDN) product relative to adult smokers who continue smoking exclusively.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tobacco Use Behavior

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Covance Daytona Clinical Research Unit, Daytona Beach, Florida, United States

Loading trial locations.

About this study

This was a randomized, controlled, open-label, parallel group, multicenter, 9-week study to determine changes in BOE in adult smokers allowed ad libitum use of an OTDN product relative to adult smokers who were not allowed to use an OTDN product. This study was conducted in adult smokers who were considered to be in overall good health. Subjects were randomized to Test (allowed OTDN use) or Control (not allowed OTDN use) groups.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject must:

  • sign an Institutional Review Board (IRB)-approved Informed Consent Form (ICF) for the study.
  • be between the ages of 21 and 65 years, inclusive, at the time of Screening.
  • have consumed a minimum of 10 manufactured cigarettes per day (CPD) daily during the last 6 months (entire 6 month period must have occurred after subject turned 21 years of age).
  • indicate that he/she smokes cigarettes "every day" at Screening and on Day 1
  • be able to fully comprehend the English language.
  • have an active phone number and must have daily access to a touchtone phone between 1600 and 1900 hours.
  • be interested in alternative tobacco products to cigarettes at Screening.
  • indicate that they "definitely would buy" or "probably would buy" on the VBM-FG2 Potential Purchase Interest Questionnaire.
  • be in generally good health.
  • if female, have a negative urine dipstick pregnancy test.
  • if female heterosexually active and of childbearing potential (i.e., not surgically sterile or two years naturally postmenopausal), agree to use a medically accepted method of contraception from Screening through the End of Study.
  • have clinical laboratory tests within the appropriate reference range or which are clinically acceptable to the Investigator.
  • have a negative ethanol, amphetamines, opiates, cannabinoids, and cocaine urine drug screen.
  • test negative for human immunodeficiency (HIV), hepatitis B (hepatitis B surface antigen [HBsAg]), and Hepatitis C (anti-hepatitis C virus antibody [anti-HCV]).
  • be willing and able to comply with the requirements of the study.

Exclusion criteria

Subject must not:

  • be pregnant, nursing, or planning to become pregnant during the study period.
  • indicate that he/she intends to quit smoking within the next 30 days (at Screening or on Day 1).
  • have uncontrolled hypertension, history of coronary heart disease or other significant heart conditions, and/or other significant medical conditions that might interfere with study procedures.
  • have used prescription anti-diabetic medication and/or insulin therapy within 12 months of Day 1.
  • have a history of drug or alcohol abuse within the 24 months prior to Screening.
  • have participated in a clinical study for an investigational drug, device, or biologic within 30 days prior to enrollment (Day 1).
  • be a current user of nicotine replacement therapy (indicate every day or some days on Subject Screener/Tobacco History Questionnaire).
  • be a current or former employee of the tobacco industry or a first-degree relative (e.g., parent, sibling, child) of a current or former employee of the tobacco industry.
  • have been involved in the development of the study design/conduct or be a first-degree relative (e.g., parent, sibling, child) of someone involved in the development of the study design/conduct.
  • be a current employee or personnel involved with the study at the study site.
  • be currently participating in the study at a different study site (i.e., each subject can only be in the study population once).

Treatment and study plan

Oral tobacco-derived nicotine product (OTDN)

Other

Other names: VERVE® Discs Blue Mint, VBM-FG2 oral discs

Primary outcomes

  1. Summary Statistics of Percent Change From Baseline for Urinary Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (%) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of percent change from baseline for urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL] (%) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

    Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a Statistical Analysis System (SAS®) procedure.

Secondary outcomes

  1. Summary Statistics of Change From Baseline for Urinary Total NNAL (ng/g Creatinine) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of change from baseline for urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL] (ng/g creatinine) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

  2. Summary Statistics of Change From Baseline for Nicotine Equivalents (mg / g Creatinine) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of change from Baseline for urinary nicotine equivalents including nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide) (mg/g creatinine) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

  3. Summary Statistics of Percent Change From Baseline for Nicotine Equivalents (%) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of percent change from Baseline for urinary nicotine equivalents including nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide) (%) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

    Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS® procedure.

  4. Summary Statistics of Change From Baseline for S-phenyl Mercapturic Acid (S-PMA) (ng/g Creatinine) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of change from Baseline for urinary S-phenyl mercapturic acid [S-PMA] (ng/g creatinine) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

  5. Summary Statistics of Percent Change From Baseline for S-PMA (%) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of percent change from Baseline for urinary S-phenyl mercapturic acid [S-PMA] (%) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

    Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS® procedure.

  6. Summary Statistics of Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of change from Baseline for blood carboxyhemoglobin (%) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

  7. Summary Statistics of Percent Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of percent change from Baseline for blood carboxyhemoglobin (%) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

    Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS® procedure.

  8. Summary Statistics of Change From Baseline for Exhaled Carbon Monoxide (Ppm) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of change from Baseline for exhaled carbon monoxide (ppm) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

  9. Summary Statistics of Percent Change From Baseline for Exhaled Carbon Monoxide (%) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of percent change from Baseline for exhaled carbon monoxide (%) in each study visit are presented.

    Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

    Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS® procedure.

  10. Summary Statistics of Change From Baseline in Cigarettes Smoked Per Day (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of change from Baseline in number or products used day in each study visit are presented.

    Values for visit are the average of daily values for the previous week Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1

  11. Summary Statistics of Percent Change From Baseline for Cigarettes Smoked Per Day (CPD) (Per-Protocol Population)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of percent change from Baseline of number of products used per day in each study visit are presented.

    CPD was tracked using an interactive voice response system (IVRS). During the Baseline Period (Days 1 to 8), subjects reported CPD daily through an IVRS each day between 16:00 and 19:00. Test and Control subjects continued daily tobacco use tracking via an IVRS and return to the study site once a week during the 4 week Product Use Period on Days 15, 22, 29, and 36.

    Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing the calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a SAS procedure.

  12. Summary Statistics of Change From Baseline for Total Score of Fagerstrom Test for Cigarette Dependence (Per-Protocol Population)

    Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Summary statistics of change from Baseline for Total Score of Fagerstrom Test for Cigarette Dependence at the end of study/early termination are presented. The Fagerstrom Test for Nicotine Dependence consists of Yes/No and multiple-choice questions where each response is assigned a value from 0 to 1 (for yes/no questions) or 0 to 3 (for multiple-choice questions). Values are summed to yield a total score with a minimum score of 0 points and a maximum score of 10 points. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.

    Baseline = Visit 3 (Day 8) value Population: Per-Protocol

  13. Count of Subjects in Subgroups Based on Change From Baseline to End of Study on Change in Quit Attempts (Per-Protocol)

    Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Count of Test and Control subjects that reported an increase, decrease or no change in quit attempts from Baseline to End of Study are presented. Results for the number of self-reported attempts to quit smoking in the previous 30 days were collected from subject responses to the question "How many times during the past 30 days have you stopped smoking cigarettes for 24 hours or longer because you were trying to quit?".

    Baseline = Visit 2 values. Population: Per-Protocol.

  14. Count of Subjects in Subgroups Based on Change From Baseline to End of Study on Change in Quitting Intentions (Per-Protocol)

    Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Count of Test and Control subjects that reported a change (No to Yes) or no change in quitting intentions from Baseline to End of Study are presented. Results were collected from subject Yes/No responses to the question "Are you planning to quit smoking in the next 30 days?".

    Baseline = Visit 2 responses. Population: Per-Protocol.

  15. Difference in Means of Urinary Total NNAL Exposure Between Day 1 and Day 8 (Per-Protocol)

    Time frame: Daily during Baseline Period (Day 1 to Day 8)

    This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.

    Difference in mean urinary total NNAL exposure between two methods for determining daily product use (Cigarettes Per Day [CPD]) during the Baseline Period:

    Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).

    Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).

    Population: Per-Protocol.

  16. Difference in Means of Nicotine Equivalents Exposure Between Day 1 and Day 8 (Per-Protocol)

    Time frame: Daily during Baseline Period (Day 1 to Day 8)

    This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.

    Difference in mean urinary nicotine equivalents exposure between two methods for determining daily product use (Cigarettes Per Day [CPD]) during the Baseline Period:

    Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).

    Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).

    Nicotine equivalents include nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide) Population: Per-Protocol.

  17. Difference in Means of S-PMA Exposure Between Day 1 and Day 8 (Per-Protocol)

    Time frame: Daily during Baseline Period (Day 1 to Day 8)

    This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.

    Difference in mean urinary S-phenylmercapturic acid [S-PMA] exposure between two methods for determining daily product use (Cigarettes Per Day [CPD]) during the Baseline Period:

    Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).

    Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).

    Population: Per-Protocol.

  18. Difference in Means of Carboxyhemoglobin (COHb) Exposure Between Day 1 and Day 8 (Per-Protocol)

    Time frame: Daily during Baseline Period (Day 1 to Day 8)

    This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.

    Difference in mean blood carboxyhemoglobin [COHb] exposure between two methods for determining daily product use (Cigarettes Per Day [CPD]) during the Baseline Period:

    Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).

    Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).

    Population: Per-Protocol.

  19. Difference in Means of Carbon Monoxide (CO) Exposure Between Day 1 and Day 8 (Per-Protocol)

    Time frame: Daily during Baseline Period (Day 1 to Day 8)

    This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.

    Difference in mean exhaled carbon monoxide [CO] between two methods for determining daily product use (Cigarettes Per Day, CPD) during the Baseline Period:

    Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).

    Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).

    Population: Per-Protocol.

  20. Difference in Cigarettes Per Day Between the Once Weekly Recall at Day 8 (From Questionnaire) and the Average Daily Tracking Days 2 Through 8 (From IVRS) (Per-Protocol)

    Time frame: Daily during Baseline Period (Day 1 to Day 8)

    This secondary objective was to compare differences in the biomarker of exposure between two methods for determining CPD during the Baseline Period.

    Difference in product use (Cigarettes Per Day [CPD]), including test product, between two methods for determining CPD during the Baseline Period:

    Method 1: Recall of average daily CPD for prior week using Past 7 Day Cigarettes Use Questionnaire (Day 1).

    Method 2: Daily CPD tracking using an interactive voice response system (IVRS; 7 day average of values recorded on Days 2 through 8).

    Population: Per-Protocol.

  21. Frequency and Percentage of Subjects With Change From Baseline in Cigarette Consumption

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)

    Change in cigarette consumption, categorized as 'No change', '<50% reduction', '50% to < 100% reduction', '100% reduction' or 'Increase', among subjects in Test and Control groups are presented. Baseline values are based on the average of daily values for the week prior to randomization (Visit 3/Day 8±1).

  22. Frequency and Percentage of Subjects With Change From Baseline in Urinary Total NNAL (ng / g Creatinine)

    Time frame: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)

    Change in Urinary Total NNAL, categorized as 'No change', 'Reduction', 'Increase' or 'Missing', among subjects in Test and Control groups are presented. Baseline values are Visit 3 (Day 8) values.

  23. Frequency and Percentage of Subjects With Change From Baseline in Quitting Intentions

    Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Change in subject quitting intentions from Baseline to End of Study are presented. Subject responses were categorized as 'No to Yes', 'Yes to No' and 'Same' (no change in quitting intention). Baseline = Visit 2 (Day 1)

  24. Summary Statistics of Cigarettes Smoked Per Day on Visits 2 (Day 1) and 3 (Day 8)

    Time frame: Day 1 (Visit 2) and Day 8 (Visit 3)

    Summary statistics of average cigarettes smoked per day [CPD] over previous 7 days collected from Cigarette Use questionnaire on Visit 2 (Day 1) and Visit 3 (Day 8) are presented.

  25. Summary Statistics of Carboxyhemoglobin by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)

    Summary statistics of blood carboxyhemoglobin in each visit among subjects in Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

  26. Summary Statistics of Exhaled Carbon Monoxide by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)

    Summary Statistics of exhaled carbon monoxide in each visit among subjects in Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

  27. Summary Statistics of S-PMA by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7)

    Summary statistics of urinary S-PMA (ng/g creatinine) in each visit among subjects in Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

  28. Descriptive Statistics for Cigarettes Smoked Per Day (CPD) (Recall Data) in Day 1 and 8 (Respectively) by Study Group and Cigarette Consumption Categories

    Time frame: Day 1 (Visit 2) and Day 8 (Visit 3)

    Descriptive statistics for Cigarettes Smoked per Day (CPD) in Day 1 (Visit 2) and Day 8 (Visit 3) in Test and Control groups using recall data are presented. Subjects were sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing').

  29. Summary Statistics of Cigarettes Smoked Per Day (IVRS Data) by Study Group and Cigarette Consumption Categories on Days 1 Through 8

    Time frame: Daily during Baseline Period (Day 1 to Day 8)

    Summary Statistics of Cigarettes Smoked per Day collected by IVRS Data method on Days 1 to 8 for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

  30. Median Change From Baseline to End of Study for Urinary Total NNAL by Study Group

    Time frame: Day 8 (Visit 3) and End of Study (Day 36±1)

    Median change from baseline to End of Study for urinary total NNAL in Test and Control groups are presented. Baseline = Day 8 (Visit 3) values.

  31. Median Change From Baseline to End of Study for Urinary Total NNAL by Study Group and Cigarette Consumption Categories

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Median Change from baseline to End of Study for urinary total NNAL in Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented. Baseline = Day 8 (Visit 3) values

  32. Change From Baseline to End of Study Summary Statistics of Urinary Total NNAL (ng/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Change from Baseline to End of Study summary statistics of urinary total NNAL (ng/g Creatinine) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented. Baseline = Visit 3 (Day 8) values.

  33. Percent Change From Baseline to End of Study Summary Statistics of Urinary Total NNAL (%) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Percent change from Baseline to End of study summary statistics of urinary total NNAL (%) for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

    Baseline = Visit 3 (Day 8) values.

  34. Change From Baseline to End of Study Summary Statistics of Nicotine Equivalents (mg/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Change from Baseline to End of Study summary statistics of urinary nicotine equivalents (mg/g creatinine) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

    Nicotine equivalents include nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide).

    Baseline = Visit 3 (Day 8) values.

  35. Percent Change From Baseline to End of Study Summary Statistics of Nicotine Equivalents (%) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Percent change from Baseline to End of study summary statistics of urinary nicotine equivalents (%) for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

    Nicotine equivalents include nicotine and its 5 metabolites (cotinine, trans-3'-hydroxycotinine, trans-3'-hydroxycotinine-0-glucuronide, nicotine-N-glucuronide, and cotinine-N-glucuronide).

    Baseline = Visit 3 (Day 8) values.

  36. Change From Baseline to End of Study Summary Statistics of S-PMA (ng/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Change from Baseline to End of Study summary statistics of urinary S-phenyl mercapturic acid [S-PMA] (ng/g creatinine) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

    Baseline = Visit 3 (Day 8) values.

  37. Percent Change From Baseline to End of Study Summary Statistics of S-PMA (%) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Percent change from Baseline to End of study summary statistics of urinary S-phenyl mercapturic acid [S-PMA] (%) for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

    Baseline = Visit 3 (Day 8) values.

  38. Change From Baseline to End of Study Summary Statistics of Carboxyhemoglobin (%) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Change from Baseline to End of Study summary statistics of blood carboxyhemoglobin (%) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented. Baseline = Visit 3 (Day 8) values.

  39. Percent Change From Baseline to End of Study Summary Statistics of Carboxyhemoglobin (%) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Percent change from Baseline to End of study summary statistics of blood carboxyhemoglobin (%) for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

    Baseline = Visit 3 (Day 8) values.

  40. Change From Baseline to End of Study Summary Statistics of Exhaled Carbon Monoxide (Ppm) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Change from Baseline to End of Study summary statistics of exhaled carbon monoxide (ppm) by Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

    Baseline = Visit 3 (Day 8) values.

  41. Percent Change From Baseline to End of Study Summary Statistics of Exhaled Carbon Monoxide (%) by Study Group and Cigarette Consumption Categories Over Visits

    Time frame: Day 8 (Visit 3) and Day 36 (Visit 7/End of Study)

    Percent change from Baseline to End of study summary statistics of exhaled carbon monoxide for Test and Control groups sub-categorized by cigarette consumption categories obtained from End of Study ('Increase', 'No Change', >50% Reduction', '50 to <100% Reduction', '100% Reduction' and 'Missing') are presented.

    Baseline = Visit 3 (Day 8) values.

  42. Characterization of Subgroups Based on Change From Baseline in Total NNAL

    Time frame: Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

    Statistical analyses on the number of subjects in subgroups based on urinary total NNAL change from baseline to the last visit are presented.

    Baseline = Visit 3 values.

Sponsors and collaborators

Lead sponsor

Altria Client Services LLC

Industry

Registry information

Official study title

A Randomized, Controlled, Parallel Group Clinical Study of Cigarette Smokers Using an Innovative Oral Tobacco-derived Nicotine Product to Determine Impact on Cigarette Consumption and Biomarkers of Exposure

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Sep 6, 2019
Registry last updated
Sep 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.